HondurasTuberculosis profile
Population  2017 9.3 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.41 (0.31–0.53) 4.5 (3.3–5.8)
Mortality (HIV+TB only) 0.05 (0.035–0.068) 0.54 (0.38–0.73)
Incidence  (includes HIV+TB) 3.5 (2.7–4.4) 38 (29–48)
Incidence (HIV+TB only) 0.24 (0.16–0.35) 2.6 (1.7–3.7)
Incidence (MDR/RR-TB)** 0.1 (0.041–0.19) 1.1 (0.44–2.1)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.21 (0.2–0.23) 1.1 (0.98–1.3) 1.4 (1.1–1.6)
Males 0.23 (0.22–0.25) 1.9 (1.6–2.3) 2.1 (1.7–2.6)
Total 0.45 (0.41–0.49) 3 (2.3–3.8) 3.5 (2.7–4.4)
TB case notifications, 2017  
Total cases notified 2 813
Total new and relapse 2 798
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 95%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 88%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.13 (0.09–0.18)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 183 7%
          - on antiretroviral therapy 175 96%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  59
(23–94)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.93–4) 4% (1.7–7.7)  
% notified tested for rifampicin resistance 41% 90% 1 273
MDR/RR-TB cases tested for resistance to second-line drugs   4
Laboratory-confirmed cases MDR/RR-TB: 21, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 18, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 88% 2 880
Previously treated cases, excluding relapse, registered in 2016 70% 10
HIV-positive TB cases registered in 2016 71% 207
MDR/RR-TB cases started on second-line treatment in 2015 67% 12
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 45%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 11
Funding source: 25% domestic, 27% international, 48% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-20 Data: www.who.int/tb/data